Cargando…

Existing Evidence for the Repurposing of PARP-1 Inhibitors in Rare Demyelinating Diseases

SIMPLE SUMMARY: Poly (ADP-ribose) polymerase-1 (PARP-1) inhibitors are successful cancer therapeutics that impair DNA repair machinery, leading to an accumulation of DNA damage and consequently cell death. The shared underlying mechanisms driving malignancy and demyelinating disease, together with t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mekhaeil, Marianna, Dev, Kumlesh Kumar, Conroy, Melissa Jane
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8833351/ https://www.ncbi.nlm.nih.gov/pubmed/35158955 http://dx.doi.org/10.3390/cancers14030687

Ejemplares similares

Olaparib Attenuates Demyelination and Neuroinflammation in an Organotypic Slice Culture Model of Metachromatic Leukodystrophy
por: Mekhaeil, Marianna, et al.
Publicado: (2023)

Investigating the Effects of Olaparib on the Susceptibility of Glioblastoma Multiforme Tumour Cells to Natural Killer Cell-Mediated Responses
por: Moran, Jennifer, et al.
Publicado: (2023)

Fingolimod Attenuates Splenocyte-Induced Demyelination in Cerebellar Slice Cultures
por: Pritchard, Adam J., et al.
Publicado: (2014)

Fingolimod Rescues Demyelination in a Mouse Model of Krabbe's Disease
por: Béchet, Sibylle, et al.
Publicado: (2020)

EBI2 receptor regulates myelin development and inhibits LPC-induced demyelination
por: Rutkowska, Aleksandra, et al.
Publicado: (2017)

The chemokine fractalkine (CX3CL1) attenuates H(2)O(2)-induced demyelination in cerebellar slices
por: O’Sullivan, Sinead A., et al.
Publicado: (2017)

The dual S1PR1/S1PR5 drug BAF312 (Siponimod) attenuates demyelination in organotypic slice cultures
por: O’Sullivan, Catherine, et al.
Publicado: (2016)

Repurposing and computational design of PARP inhibitors as SARS-CoV-2 inhibitors
por: Rampogu, Shailima, et al.
Publicado: (2023)

Hybrid Nanoparticles as a Novel Tool for Regulating Psychosine-Induced Neuroinflammation and Demyelination In Vitro and Ex vivo
por: Clementino, Adryana, et al.
Publicado: (2021)

Phospholipase A2 is involved in galactosylsphingosine-induced astrocyte toxicity, neuronal damage and demyelination
por: Misslin, Cedric, et al.
Publicado: (2017)

Novel CMKLR1 Inhibitors for Application in Demyelinating Disease
por: Kumar, Vineet, et al.
Publicado: (2019)

Pre-Existing and Acquired Resistance to PARP Inhibitor-Induced Synthetic Lethality
por: Le, Bac Viet, et al.
Publicado: (2022)

Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma
por: Kanakkanthara, Arun, et al.
Publicado: (2022)

Repurposing Existing Drugs for the Treatment of COVID-19
por: Farne, Hugo, et al.
Publicado: (2020)

Repurposing existing drugs: identification of irreversible IMPDH inhibitors by high-throughput screening
por: Sarwono, Albertus Eka Yudistira, et al.
Publicado: (2018)

The Effects of Antipsychotics in Experimental Models of Krabbe Disease
por: Sharma, Kapil, et al.
Publicado: (2023)

In silico approaches for drug repurposing in oncology: Protocol for a scoping review of existing evidence
por: Cavalcante, Bruno Raphael Ribeiro, et al.
Publicado: (2022)

PARP inhibitors
por: Anwar, Maheen, et al.
Publicado: (2015)

PARP Inhibitors in Metastatic Prostate Cancer: Evidence to Date
por: Nizialek, Emily, et al.
Publicado: (2020)

PARP1 in Carcinomas and PARP1 Inhibitors as Antineoplastic Drugs
por: Wang, Luyao, et al.
Publicado: (2017)

Interactions of PARP1 Inhibitors with PARP1-Nucleosome Complexes
por: Maluchenko, Natalya, et al.
Publicado: (2022)

Evolution of Pre-Existing versus Acquired Resistance to Platinum Drugs and PARP Inhibitors in BRCA-Associated Cancers
por: Yamamoto, Kimiyo N., et al.
Publicado: (2014)

Repurposing existing drugs for COVID-19: an endocrinology perspective
por: Cadegiani, Flavio A.
Publicado: (2020)

Repurposing of existing FDA approved drugs for Neprilysin inhibition: An in-silico study
por: Sankhe, Runali, et al.
Publicado: (2021)

PARP inhibitors: the race is on
por: Brown, Jessica S, et al.
Publicado: (2016)

PARP Inhibitors in Prostate and Urothelial Cancers
por: Garje, Rohan, et al.
Publicado: (2020)

Repurposing existing drugs: identification of SARS-CoV-2 3C-like protease inhibitors
por: Chiou, Wei-Chung, et al.
Publicado: (2021)

Targeting S1P receptors in experimental autoimmune encephalomyelitis in mice improves early deficits in locomotor activity and increases ultrasonic vocalisations
por: Sheridan, Graham K., et al.
Publicado: (2014)

Biomarkers in Rare Demyelinating Disease of the Central Nervous System
por: Boziki, Marina, et al.
Publicado: (2020)

RNA interference as a therapeutic strategy for treating CNS disorders
por: Hoyer, Daniel, et al.
Publicado: (2006)

Repurposing paclitaxel for the treatment of fibrosis: indication discovery for existing drugs
por: Chen, Xiao-Wu, et al.
Publicado: (2015)

Repurposing existing drugs for monkeypox: applications of virtual screening methods
por: Li, Vladimir, et al.
Publicado: (2023)

Serine-linked PARP1 auto-modification controls PARP inhibitor response
por: Prokhorova, Evgeniia, et al.
Publicado: (2021)

PARP inhibitors in ovarian cancer: Clinical evidence for informed treatment decisions
por: Ledermann, Jonathan A, et al.
Publicado: (2015)

Fingolimod Rescues Memory and Improves Pathological Hallmarks in the 3xTg-AD Model of Alzheimer’s Disease
por: Fagan, Steven G., et al.
Publicado: (2022)

PARP inhibitors trap PARP2 and alter the mode of recruitment of PARP2 at DNA damage sites
por: Lin, Xiaohui, et al.
Publicado: (2022)

PARP inhibitors are not all equal
por: Dent, Paul
Publicado: (2013)

PARP inhibitors in ovarian cancer
por: Cibula, David, et al.
Publicado: (2015)

Dual Inhibitors of PARPs and ROCKs
por: Antolín, Albert A., et al.
Publicado: (2018)

Reverse the Resistance to PARP Inhibitors
por: Kim, Yevgeniy, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_l588c9knq91sctqt05120efnat